Zydus Lifesciences shareholding pattern

Who owns itSep 2026 quarter

Promoters75.01%no change
Foreign investors (FII)7.05%+0.17 pts
Domestic institutions (DII)11.28%+0.01 pts
of which mutual funds6.88%+1.76 pts
of which insurance companies4.20%
Public6.66%

Per cent of all shares; change on the Jun 2026 quarter, in percentage points. As filed with the exchanges.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ZYDUSLIFE₹1,175.50

Zydus Lifesciences Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMADRREDDYCIPLATORNTPHARMDIVISLABMAXHEALTHAPOLLOHOSPAUROPHARMAMcap ₹1.18L Cr
Holding % of Total Shares
12 Months Ending
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
18/06/2026
Q1 FY27
30/06/2026
Q2 FY27
30/09/2026
Promoter & Group74.9874.9874.9974.9974.9975.0075.0075.0175.0175.01
FII / FPI7.527.537.327.137.347.066.956.896.887.05
DII10.6510.6511.0111.1310.8611.0911.2011.1911.2711.28
Mutual Funds6.576.326.365.564.704.714.884.925.126.88
Latest: 2026-09-30 · 62 quarters of history · click a row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.